

Atty. Dkt. No. 025217-0122

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**

Claims 1-35 (Canceled)

36. (New) An apparatus for applying a physiologically active agent or prodrug thereof to a dermal surface or mucosal membrane of an animal, said apparatus comprising (A) a container and, in said container, (B) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises:

(1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof; and

(2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface or membrane and (ii) is of low toxicity to and is tolerated by the dermal surface or mucosal membrane of the animal, and wherein, after application of the system to an area of the dermal surface or mucosal membrane, the area becomes touch-dry within three minutes of application.

37 (New) The apparatus of claim 36, wherein the dermal penetration enhancer is one or more esters selected from the group consisting of C<sub>8</sub> to C<sub>18</sub> alkyl para-aminobenzoate, C<sub>8</sub> to C<sub>18</sub> alkyl dimethyl-para-aminobenzoate, C<sub>8</sub> to C<sub>18</sub> alkyl cinnamate, C<sub>8</sub> to C<sub>18</sub> alkyl methoxycinnamate and C<sub>8</sub> to C<sub>18</sub> alkyl salicylate.

38. (New) The apparatus of claim 36, wherein the container further comprises a pharmaceutical-grade spray nozzle.

Atty. Dkt. No. 025217-0122

39. (New) The apparatus of claim 38, wherein the container is an aerosol container that contains a propellant for dispensing the drug delivery system as an aerosol.

40. (New) The apparatus of claim 38, wherein the container further comprises a shroud that is configured (A) to maintain the nozzle at a predetermined height above and perpendicular to the dermal surface or mucosal membrane and (B) to enclose the area between the nozzle and the dermal surface or mucosal membrane.

41. (New) The apparatus of claim 40, wherein the shroud defines an area on the dermal surface or mucosal membrane that is substantially circular in shape.

42. (New) The apparatus of claim 36, wherein the apparatus provides one or more metered doses of the drug delivery system.

43. (New) The apparatus of claim 42, wherein the apparatus comprises a pharmaceutical grade metered dose valve.

44. (New) The apparatus of claim 42, wherein the apparatus provides one or more fixed metered doses of the drug delivery system.


44. (New) The apparatus of claim 42, wherein the apparatus provides one or more variable metered doses of the drug delivery system.

45. (New) The apparatus of claim 36, wherein the dermal surface or mucosal membrane becomes touch-dry within 1 minute of application of the drug delivery system.

46. (New) The apparatus of claim 36, wherein the dermal penetration enhancer is a safe skin tolerant sunscreen.

Atty. Dkt. No. 025217-0122

47. (New) The apparatus of claim 36, wherein the dermal penetration enhancer is an ester of formula (I):



wherein R<sup>1</sup> is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR<sup>3</sup>R<sup>4</sup>;  
 R<sup>2</sup> is a long chain alkyl;  
 R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, lower alkyl or R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring;  
 n is 0 or 1; and  
 q is 1 or 2.

48. (New) The apparatus of claim 36, wherein the dermal penetration enhancer is one or more esters selected from the group consisting of a long chain alkyl para-aminobenzoate, long chain alkyl dimethyl-para-aminobenzoate, long chain alkyl cinnamate, long chain alkyl methoxycinnamate and long chain alkyl salicylate.

49. (New) The apparatus of claim 48, wherein the dermal penetration enhancer is one or more esters selected from the group consisting of octyl dimethyl-para-aminobenzoate, octyl para-methoxycinnamate and octyl salicylate.

50. (New) The apparatus of claim 36, wherein the volatile liquid is ethanol or isopropanol.

51. (New) The apparatus of claim 36, wherein the physiologically active agent is a steroid, hormone derivative, non-steroidal anti-inflammatory drug, opioid analgesic, antinauseant, antioestrogen, aromatase inhibitor, 5-alpha reductase inhibitor, anxiolytic, prostaglandin, anti-viral drug, anti-migraine compound, antihypertensive agent, anti-malarial compound, bronchodilator, anti-depressant, anti-Alzheimer's agent, neuroleptic and antipsychotic agent, anti-Parkinson's agent, anti-androgen or anorectic agent.

Atty. Dkt. No. 025217-0122

52. (New) The apparatus of claim 36, wherein the physiologically active agent is testosterone, oestradiol, ethinyloestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstanedione and its derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, alprostadil, prostacyclin and its derivatives, melatonin, n-docosanol, tromantadine, lipophilic pro-drugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil, minoxidil pro-drugs, pilocarpine, salbutamol, terbutaline, salmeterol, ibogaine, bupropian, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate or mazindol.

53. (New) The apparatus of claim 36, wherein the drug delivery system further comprises one or more components selected from the group consisting of a pharmaceutical compounding agent, co-solvent, surfactant, emulsifier, antioxidant, preservative, stabiliser, diluent, and mixtures of two or more of said components.

54. (New) An apparatus for applying a physiologically active agent or prodrug thereof through a body surface of an animal, which apparatus comprises a container that contains a pharmaceutical formulation comprised of (i) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and (ii) at least one dermal penetration enhancer and at least one volatile liquid which, in combination, enable the formulation to dry within three minutes of application to the body surface and to provide for transport of the active agent or prodrug during and/or subsequent to drying.